Leflunomide-d₄

Cat. No.: HY-B0083S: FAQs
Data Sheet Handling Instructions Technical Support

Leflunomide-d₄ (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent[1][2].

For research use only. We do not sell to patients.

Leflunomide-d<sub>4</sub> Chemical Structure

Leflunomide-d₄ Chemical Structure

CAS No. : 1189987-23-2

Size	Price	Stock	Quantity
500 μg		Get quote 3 - 4 weeks 4 - 5 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Leflunomide-d₄:

Leflunomide In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	Leflunomide-d₄ (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent[1][2].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Leflunomide-d₄ Related Antibodies
Molecular Weight	274.23
Formula	C₁₂H₅D₄F₃N₂O₂
CAS No.	1189987-23-2
Unlabeled CAS	75706-12-6
SMILES	C(NC1=C(C(=C(C(F)(F)F)C(=C1[2H])[2H])[2H])[2H])(=O)C2=C(C)ON=C2
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (270 KB) Handling Instructions (2659 KB)
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief] [2]. Davis JP, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35(4):1270-3. [Content Brief] [3]. Xu X, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem. 1995 May 26;270(21):12398-403. [Content Brief] [4]. Fox RI, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999 Dec;93(3):198-208. [Content Brief]